

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07160179

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	AbbVie
Enrollment	66 participants

Key Eligibility Criteria

Inclusion (8)

- Stage 1 and Stage 2
- Diagnosed with Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in the study eye.
- Stage 1
- Foveal or non-foveal GA with total GA lesion area ≤ 0.5 DA (1.25 mm²) in the study eye, as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline/Day 1
- Absence of choroidal neovascularization (CNV) in the study eye as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline/Day 1. In addition, investigators should confirm eligibility prior to treatment administration on Baseline/Day 1.

... and 3 more (see full listing online)

Exclusion (4)

- Stage 1 and Stage 2
- History of recurrent or currently active ocular or intraocular inflammation (e.g., uveitis, endophthalmitis) in at least one eye at Screening and Baseline/Day 1.
- Active periocular, ocular, or intraocular infection in at least one eye at Baseline/Day 1.
- History or clinical signs of diabetic retinopathy, diabetic macular edema (DME), or any retinal vascular disease other than AMD in at least one eye at Screening and Baseline/Day 1.

Locations (4 total)

Retina Partners Midwest, P.C. /ID# 262172, Carmel, Indiana, United States
Retina Research Institute of Texas /ID# 262141, Abilene, Texas, United States
Retina Foundation of the Southwest /ID# 262479, Dallas, Texas, United States

... and 1 more locations